These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24083612)

  • 41. GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study.
    Van der Bij AK; Kloosterboer N; Prins M; Boeser-Nunnink B; Geskus RB; Lange JM; Coutinho RA; Schuitemaker H
    J Infect Dis; 2005 Mar; 191(5):678-85. PubMed ID: 15688280
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perturbations induced by synthetic peptides from hepatitis G virus structural proteins in lipid model membranes: a fluorescent approach.
    Larios C; Casas J; Mestres C; Haro I; Alsina MA
    Luminescence; 2005; 20(4-5):279-81. PubMed ID: 16134194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1.
    Xiang J; George SL; Wünschmann S; Chang Q; Klinzman D; Stapleton JT
    Lancet; 2004 Jun; 363(9426):2040-6. PubMed ID: 15207954
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activation of interferon response genes and of plasmacytoid dendritic cells in HIV-1 positive subjects with GB virus C co-infection.
    Lalle E; Sacchi A; Abbate I; Vitale A; Martini F; D'Offizi G; Antonucci G; Castilletti C; Poccia F; Capobianchi MR
    Int J Immunopathol Pharmacol; 2008; 21(1):161-71. PubMed ID: 18336742
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GB virus C and HIV-1 RNA load in single virus and co-infected West African individuals.
    Li C; Collini P; Danso K; Owusu-Ofori S; Dompreh A; Candotti D; Opare-Sem O; Allain JP
    AIDS; 2006 Feb; 20(3):379-86. PubMed ID: 16439871
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile.
    Nunnari G; Nigro L; Palermo F; Attanasio M; Berger A; Doerr HW; Pomerantz RJ; Cacopardo B
    Ann Intern Med; 2003 Jul; 139(1):26-30. PubMed ID: 12834315
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural Study of a New HIV-1 Entry Inhibitor and Interaction with the HIV-1 Fusion Peptide in Dodecylphosphocholine Micelles.
    Pérez Y; Gómara MJ; Yuste E; Gómez-Gutierrez P; Pérez JJ; Haro I
    Chemistry; 2017 Aug; 23(48):11703-11713. PubMed ID: 28677862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GB virus C genotype 2 predominance in a hepatitis C virus/HIV infected population associated with reduced liver disease.
    Berzsenyi MD; Bowden DS; Roberts SK; Revill PA
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1407-10. PubMed ID: 19702909
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Frequency and genotype of GB virus C among Iranian patients infected with HIV.
    Hekmat S; Mohraz M; Vahabpour R; Jam S; Bahramali G; Banifazl M; Aghakhani A; Eslamifar A; Mahboudi F; Edalat R; Ramezani A
    J Med Virol; 2008 Nov; 80(11):1941-6. PubMed ID: 18814233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short communication: Evaluation of GB virus C/hepatitis G viral load among HIV type 1-coinfected patients in São Paulo, Brazil.
    Alves-Sousa VK; Komninakis SC; Baggio-Zappia GL; Barbosa AJ; Mantovani NP; Diaz RS; Abrão P; Lanzara GA; Granato CF
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1301-4. PubMed ID: 22242901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C.
    Sánchez-Martín MJ; Hristova K; Pujol M; Gómara MJ; Haro I; Alsina MA; Busquets MA
    J Colloid Interface Sci; 2011 Aug; 360(1):124-31. PubMed ID: 21565353
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phylogenetic diversity of GB virus C at the antigenic site of E2 protein.
    Wu H; Tien P; Gong X
    Virus Res; 2013 Dec; 178(2):502-505. PubMed ID: 24512753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of early and late GB virus C viraemia on survival of HIV-infected individuals: a meta-analysis.
    Zhang W; Chaloner K; Tillmann HL; Williams CF; Stapleton JT
    HIV Med; 2006 Apr; 7(3):173-80. PubMed ID: 16494631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of GB virus C, HIV, and HCV infection markers in hemophiliacs exposed to non-inactivated or inactivated factor concentrates.
    Kupfer B; Ruf T; Matz B; Nattermann J; Spengler U; Rockstroh JK; Brackmann HH; Blümel J; Tacke M; Kaiser R
    J Clin Virol; 2005 Sep; 34(1):42-7. PubMed ID: 16087123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.
    Brumme ZL; Chan KJ; Dong WW; Mo T; Wynhoven B; Hogg RS; Montaner JS; O'Shaughnessy MV; Harrigan PR
    AIDS; 2002 Sep; 16(14):1929-33. PubMed ID: 12351953
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence and distribution of the GBV-C/HGV among HIV-1-infected patients under anti-retroviral therapy.
    Alcalde R; Nishiya A; Casseb J; Inocêncio L; Fonseca LA; Duarte AJ
    Virus Res; 2010 Aug; 151(2):148-52. PubMed ID: 20420864
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
    Sheng WH; Hung CC; Wu RJ; Wang JT; Chen PJ; Chang SC; Kao JH
    Clin Infect Dis; 2007 Feb; 44(4):584-90. PubMed ID: 17243064
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
    Eckert DM; Kim PS
    Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11187-92. PubMed ID: 11572974
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II.
    Luo Z; Fan X; Zhou N; Hiraoka M; Luo J; Kaji H; Huang Z
    Biochemistry; 2000 Nov; 39(44):13545-50. PubMed ID: 11063591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.